ArticleHuman genomics2025
Clinical and prognostic significance of m6A hypomethylation and IGF2BP3 overexpression in gastric cancer: an integrated epigenomic-transcriptomic analysis.
Article in Human genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Brusatol suppresses meningioma progression via targeting HMGCR to restrict the cholesterol biosynthesis and inhibit PI3K/AKT signaling pathway.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundGastric cancer (GC) ranks as the fifth most prevalent malignancy and the third leading cause of cancer-related mortality worldwide, with complex pathogenesis driven by genetic and epigenetic alterations. While genetic contributors to GC have been extensively studied, the functional role of N6-methyladenosine (m6A) RNA methylation-the most abundant eukaryotic RNA modification-in gastric carcinogenesis remains insufficiently characterized. This study aimed to investigate transcriptome-wide m6A methylation dysregulation and its mechanistic implications in GC progression.
methodsMethylated RNA immunoprecipitation sequencing (MeRIP-seq) was performed to map m6A epitranscriptomes in paired GC and adjacent normal tissues. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were conducted on 253 hypomethylated mRNAs to delineate the biological pathways associated with m6A dysregulation. The transcriptomic profiles were analyzed using RNA-seq, while a retrospective cohort analysis (n = 58) evaluated the correlations between IGF2BP3 expression and the clinicopathological characteristics of patients with GC.
resultsMeRIP-seq analysis demonstrated transcriptome-wide m6A hypomethylation in GC tissues, identifying 271 significantly reduced peaks (p < 0.01). Functional annotation revealed enrichment of hypomethylated transcripts in metabolic pathways and transcriptional dysregulation. Notably, m6A-related genes exhibited widespread activation in GC, with IGF2BP3 showing the most pronounced upregulation (106-fold increase, p < 0.0001). Clinically, elevated IGF2BP3 expression significantly correlated with lymph node involvement (p = 0.016) and advanced TNM staging (p = 0.028).
conclusionThis study establishes m6A methylation dysregulation as a critical mechanism in GC pathogenesis and identifies IGF2BP3 as both a potential therapeutic target and a prognostic biomarker in GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.